FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2483-2494 December 25, 2003 Number 26 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Glass, D. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both.

Methods We subjected purified plasma cells from the bone marrow of patients with newly diagnosed multiple myeloma and control subjects to oligonucleotide microarray profiling and biochemical and immunohistochemical analyses to identify molecular determinants of osteolytic lesions.

Results We studied 45 control subjects, 36 patients with multiple myeloma in whom focal lesions of bone could not be detected by magnetic resonance imaging (MRI), and 137 patients in whom MRI detected such lesions. Different patterns of expression of 57 of approximately 10,000 genes from purified myeloma cells could be used to distinguish the two groups of patients (P<0.001). Permutation analysis, which adjusts the significance level to account for multiple comparisons in the data sets, showed that 4 of these 57 genes were significantly overexpressed by plasma cells from patients with focal lesions. One of these genes, dickkopf 1 (DKK1), and its corresponding protein (DKK1) were studied in detail because DKK1 is a secreted factor that has been linked to the function of osteoblasts. Immunohistochemical analysis of bone marrow–biopsy specimens showed that only myeloma cells contained detectable DKK1. Elevated DKK1 levels in bone marrow plasma and peripheral blood from patients with multiple myeloma correlated with the gene-expression patterns of DKK1 and were associated with the presence of focal bone lesions. Recombinant human DKK1 or bone marrow serum containing an elevated level of DKK1 inhibited the differentiation of osteoblast precursor cells in vitro.

Conclusions The production of DKK1, an inhibitor of osteoblast differentiation, by myeloma cells is associated with the presence of lytic bone lesions in patients with multiple myeloma.

Source Information

From the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy (E.T., F.Z., B.B., J.D.S.), and the Departments of Radiology (R.W.) and Pathology (Y.M.), College of Medicine, University of Arkansas for Medical Sciences, Little Rock; and Cancer Research and Biostatistics, Seattle (E.R.).

Mr. Tian and Dr. Zhan contributed equally to the article.

Address reprint requests to Dr. Shaughnessy at the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, or at jshaughnessy{at}uams.edu.

Full Text of this Article

Related Letters:

DKK1 in Multiple Myeloma
Meyer M. A., Hofbauer L. C., Neubauer A., Schoppet M., Lu C. M., Walker R. C., Barlogie B., Shaughnessy J. Jr.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:1464-1466, Apr 1, 2004. Correspondence

This article has been cited by other articles:

• Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D. Jr, van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J., Barlogie, B. (2009). F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114: 2068-2076 [Abstract] [Full Text]  
• Pennisi, A., Ling, W., Li, X., Khan, S., Shaughnessy, J. D. Jr, Barlogie, B., Yaccoby, S. (2009). The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 114: 1803-1812 [Abstract] [Full Text]  
• Terpos, E., Sezer, O., Croucher, P. I., Garcia-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Blade, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A., Sonneveld, P. (2009). The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20: 1303-1317 [Abstract] [Full Text]  
• Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-t., Chauhan, D., Mitsiades, C., Prabhala, R., Raje, N., Anderson, K. C., Stover, D. R., Munshi, N. C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379 [Abstract] [Full Text]  
• Saless, N., Litscher, S. J., Franco, G. E. L., Houlihan, M. J., Sudhakaran, S., Raheem, K. A., O'Neil, T. K., Vanderby, R., Demant, P., Blank, R. D. (2009). Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval. FASEB J. 23: 2142-2154 [Abstract] [Full Text]  
• Hardy, R, Cooper, M S (2009). Bone loss in inflammatory disorders. J Endocrinol 201: 309-320 [Abstract] [Full Text]  
• Liu, C.-C., Pearson, C., Bu, G. (2009). Cooperative Folding and Ligand-binding Properties of LRP6 {beta}-Propeller Domains. J. Biol. Chem. 284: 15299-15307 [Abstract] [Full Text]  
• Hideshima, T., Chauhan, D., Kiziltepe, T., Ikeda, H., Okawa, Y., Podar, K., Raje, N., Protopopov, A., Munshi, N. C., Richardson, P. G., Carrasco, R. D., Anderson, K. C. (2009). Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113: 5228-5236 [Abstract] [Full Text]  
• Schinner, S., Willenberg, H. S, Schott, M., Scherbaum, W. A (2009). Pathophysiological aspects of Wnt-signaling in endocrine disease. Eur J Endocrinol 160: 731-737 [Abstract] [Full Text]  
• Qiang, Y.-W., Hu, B., Chen, Y., Zhong, Y., Shi, B., Barlogie, B., Shaughnessy, J. D. Jr (2009). Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling. Blood 113: 4319-4330 [Abstract] [Full Text]  
• Ashihara, E., Kawata, E., Nakagawa, Y., Shimazaski, C., Kuroda, J., Taniguchi, K., Uchiyama, H., Tanaka, R., Yokota, A., Takeuchi, M., Kamitsuji, Y., Inaba, T., Taniwaki, M., Kimura, S., Maekawa, T. (2009). {beta}-Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model. Clin. Cancer Res. 15: 2731-2738 [Abstract] [Full Text]  
• Dobbin, K. K. (2009). A method for constructing a confidence bound for the actual error rate of a prediction rule in high dimensions. Biostatistics 10: 282-296 [Abstract] [Full Text]  
• Silvestris, F., Ciavarella, S., De Matteo, M., Tucci, M., Dammacco, F. (2009). Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. The Oncologist 14: 264-275 [Abstract] [Full Text]  
• Sezer, O. (2009). Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment. The Oncologist 14: 276-283 [Abstract] [Full Text]  
• Quintas-Cardama, A., Cortes, J. (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630 [Abstract] [Full Text]  
• Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., Shaughnessy, J. D. Jr (2009). The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525 [Abstract] [Full Text]  
• Chen, B., Wu, H., Zeng, Y., Freeman, J. E III, Herman, D., Shaughnessy, J. D. Jr., Barlogie, B., Epstein, J. (2008). Myeloma and Osteolytic Bone Disease: Is DKK1 All It Takes?.. ASH ANNUAL MEETING ABSTRACTS 112: 1695-1695 [Abstract]  
• Entin, I., Herman, D., Williams, D. R., Freeman, J., Shaughnessy, J. D Jr., Barlogie, B., Epstein, J. (2008). Myeloma Cell Interaction with Mesenchymal Stem Cells: Heterogeneity of Myeloma Cell Survival and Gene Expression Studies. ASH ANNUAL MEETING ABSTRACTS 112: 2738-2738 [Abstract]  
• Barlogie, B., Epstein, J., Shaughnessy, J. D. Jr (2008). Going with the flow, and beyond, in myeloma. Blood 112: 3917-3918 [Full Text]  
• Xiong, W., Wu, X., Starnes, S., Johnson, S. K., Haessler, J., Wang, S., Chen, L., Barlogie, B., Shaughnessy, J. D. Jr, Zhan, F. (2008). An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112: 4235-4246 [Abstract] [Full Text]  
• Silvestris, F., Cafforio, P., De Matteo, M., Calvani, N., Frassanito, M. A., Dammacco, F. (2008). Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. Clin. Cancer Res. 14: 6081-6091 [Abstract] [Full Text]  
• Clines, G., Kingsley, L. A. (2008). Novel Targets for and Mechanisms of Bone Metastasis: Meeting Report from Skeletal Complications of Malignancy V: October 25-27, 2007 in Philadelphia, Pennsylvania, USA. IBMS BoneKEy 5: 297-301 [Full Text]  
• Edwards, C. M. (2008). Wnt signaling: bone's defense against myeloma. Blood 112: 216-217 [Full Text]  
• Qiang, Y.-W., Shaughnessy, J. D. Jr, Yaccoby, S. (2008). Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-382 [Abstract] [Full Text]  
• Gregory, C. (2008). MM-induced osteolysis: partners in crime. Blood 112: 3-4 [Full Text]  
• Qiang, Y.-W., Chen, Y., Stephens, O., Brown, N., Chen, B., Epstein, J., Barlogie, B., Shaughnessy, J. D. Jr (2008). Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207 [Abstract] [Full Text]  
• Kim, K.-A., Wagle, M., Tran, K., Zhan, X., Dixon, M. A., Liu, S., Gros, D., Korver, W., Yonkovich, S., Tomasevic, N., Binnerts, M., Abo, A. (2008). R-Spondin Family Members Regulate the Wnt Pathway by a Common Mechanism. Mol. Biol. Cell 19: 2588-2596 [Abstract] [Full Text]  
• Morales, A. A., Gutman, D., Lee, K. P., Boise, L. H. (2008). BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111: 5152-5162 [Abstract] [Full Text]  
• Datta, H K, Ng, W F, Walker, J A, Tuck, S P, Varanasi, S S (2008). The cell biology of bone metabolism. J. Clin. Pathol. 61: 577-587 [Abstract] [Full Text]  
• Garnero, P. (2008). New Biochemical Markers of Bone Turnover. IBMS BoneKEy 5: 84-102 [Abstract] [Full Text]  
• Edwards, C. M., Edwards, J. R., Lwin, S. T., Esparza, J., Oyajobi, B. O., McCluskey, B., Munoz, S., Grubbs, B., Mundy, G. R. (2008). Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842 [Abstract] [Full Text]  
• Day, T. F., Yang, Y. (2008). Wnt and Hedgehog Signaling Pathways in Bone Development. JBJS 90: 19-24 [Abstract] [Full Text]  
• Roodman, G. D. (2008). Skeletal Imaging and Management of Bone Disease. ASH Education Book 2008: 313-319 [Abstract] [Full Text]  
• Mahtouk, K., Hose, D., De Vos, J., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T., Goldschmidt, H., Klein, B. (2007). Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications. Clin. Cancer Res. 13: 7289-7295 [Abstract] [Full Text]  
• Martin, T. J., Ng, K. W. (2007). New Agents for the Treatment of Osteoporosis. IBMS BoneKEy 4: 287-298 [Abstract] [Full Text]  
• Yang, Y., MacLeod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z., Venkataraman, G., Sasisekharan, R., Naggi, A., Torri, G., Casu, B., Vlodavsky, I., Suva, L. J., Epstein, J., Yaccoby, S., Shaughnessy, J. D. Jr, Barlogie, B., Sanderson, R. D. (2007). The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110: 2041-2048 [Abstract] [Full Text]  
• Aguilera, O., Pena, C., Garcia, J. M., Larriba, M. J., Ordonez-Moran, P., Navarro, D., Barbachano, A., Lopez de Silanes, I., Ballestar, E., Fraga, M. F., Esteller, M., Gamallo, C., Bonilla, F., Gonzalez-Sancho, J. M., Munoz, A. (2007). The Wnt antagonist DICKKOPF-1 gene is induced by 1{alpha},25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28: 1877-1884 [Abstract] [Full Text]  
• Qian, J., Xie, J., Hong, S., Yang, J., Zhang, L., Han, X., Wang, M., Zhan, F., Shaughnessy, J. D. Jr, Epstein, J., Kwak, L. W., Yi, Q. (2007). Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110: 1587-1594 [Abstract] [Full Text]  
• Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Donofrio, G., Bonomini, S., Sala, R., Mangoni, M., Rizzoli, V. (2007). Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment. Cancer Res. 67: 7665-7674 [Abstract] [Full Text]  
• Terpos, E., Sezer, O., Croucher, P., Dimopoulos, M.-A. (2007). Myeloma bone disease and proteasome inhibition therapies. Blood 110: 1098-1104 [Abstract] [Full Text]  
• Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A., Rizzoli, V. (2007). The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110: 334-338 [Abstract] [Full Text]  
• Baron, R., Rawadi, G. (2007). Targeting the Wnt/{beta}-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton. Endocrinology 148: 2635-2643 [Abstract] [Full Text]  
• Colla, S., Zhan, F., Xiong, W., Wu, X., Xu, H., Stephens, O., Yaccoby, S., Epstein, J., Barlogie, B., Shaughnessy, J. D. Jr (2007). The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109: 4470-4477 [Abstract] [Full Text]  
• Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M., Yoneda, T. (2007). Hypoxia and Hypoxia-Inducible Factor-1 Expression Enhance Osteolytic Bone Metastases of Breast Cancer. Cancer Res. 67: 4157-4163 [Abstract] [Full Text]  
• Standal, T., Abildgaard, N., Fagerli, U.-M., Stordal, B., Hjertner, O., Borset, M., Sundan, A. (2007). HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109: 3024-3030 [Abstract] [Full Text]  
• Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J. D. Jr, Epstein, J., van Hemert, R., Erdem, E., Hoering, A., Crowley, J., Ferris, E., Hollmig, K., van Rhee, F., Zangari, M., Pineda-Roman, M., Mohiuddin, A., Yaccoby, S., Sawyer, J., Angtuaco, E. J. (2007). Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. JCO 25: 1121-1128 [Abstract] [Full Text]  
• Bodine, P. V. (2007). Wnt Signaling in Bone. IBMS BoneKEy 4: 108-123 [Abstract] [Full Text]  
• Gregory, C. (2007). Advances in myeloma therapy: breaking the cycle. Blood 109: 1798-1798 [Full Text]  
• Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., Shaughnessy, J. D. Jr (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111 [Abstract] [Full Text]  
• Clines, G. A., Mohammad, K. S., Bao, Y., Stephens, O. W., Suva, L. J., Shaughnessy, J. D. Jr., Fox, J. W., Chirgwin, J. M., Guise, T. A. (2007). Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation. Mol. Endocrinol. 21: 486-498 [Abstract] [Full Text]  
• Liu, Y., Bhat, R. A., Seestaller-Wehr, L. M., Fukayama, S., Mangine, A., Moran, R. A., Komm, B. S., Bodine, P. V. N., Billiard, J. (2007). The Orphan Receptor Tyrosine Kinase Ror2 Promotes Osteoblast Differentiation and Enhances ex Vivo Bone Formation. Mol. Endocrinol. 21: 376-387 [Abstract] [Full Text]  
• Schwaninger, R., Rentsch, C. A., Wetterwald, A., van der Horst, G., van Bezooijen, R. L., van der Pluijm, G., Lowik, C. W.G.M., Ackermann, K., Pyerin, W., Hamdy, F. C., Thalmann, G. N., Cecchini, M. G. (2007). Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases. Am. J. Pathol. 170: 160-175 [Abstract] [Full Text]  
• Richardson, P. G., Hideshima, T., Anderson, K. C. (2007). Plasma cell dyscrasias. ASH-SAP 2007: 298-327 [Full Text]  
• Giuliani, N., Rizzoli, V., Roodman, G. D. (2006). Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108: 3992-3996 [Abstract] [Full Text]  
• Singhal, S., Mehta, J. (2006). Multiple Myeloma. CJASN 1: 1322-1330 [Abstract] [Full Text]  
• Guise, T. A., Mohammad, K. S., Clines, G., Stebbins, E. G., Wong, D. H., Higgins, L. S., Vessella, R., Corey, E., Padalecki, S., Suva, L., Chirgwin, J. M. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.. Clin. Cancer Res. 12: 6213s-6216s [Abstract] [Full Text]  
• Roodman, G. D. (2006). New potential targets for treating myeloma bone disease.. Clin. Cancer Res. 12: 6270s-6273s [Abstract] [Full Text]  
• Pearse, R. N. (2006). Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.. Clin. Cancer Res. 12: 6274s-6278s [Abstract] [Full Text]  
• Yeh, H. S., Berenson, J. R. (2006). Treatment for myeloma bone disease.. Clin. Cancer Res. 12: 6279s-6284s [Abstract] [Full Text]  
• Christodoulides, C., Laudes, M., Cawthorn, W. P., Schinner, S., Soos, M., O'Rahilly, S., Sethi, J. K., Vidal-Puig, A. (2006). The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis. J. Cell Sci. 119: 2613-2620 [Abstract] [Full Text]  
• Halfdanarson, T. R., Hogan, W. J., Moynihan, T. J. (2006). Oncologic Emergencies: Diagnosis and Treatment. Mayo Clin Proc. 81: 835-848 [Abstract] [Full Text]  
• Si, W., Kang, Q., Luu, H. H., Park, J. K., Luo, Q., Song, W.-X., Jiang, W., Luo, X., Li, X., Yin, H., Montag, A. G., Haydon, R. C., He, T.-C. (2006). CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells. Mol. Cell. Biol. 26: 2955-2964 [Abstract] [Full Text]  
• Spencer, G. J., Utting, J. C., Etheridge, S. L., Arnett, T. R., Genever, P. G. (2006). Wnt signalling in osteoblasts regulates expression of the receptor activator of NF{kappa}B ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 119: 1283-1296 [Abstract] [Full Text]  
• Matsumoto, T., Abe, M. (2006). Myeloma-Bone Interaction: A Vicious Cycle. IBMS BoneKEy 3: 8-14 [Abstract] [Full Text]  
• Vessella, R. L., Guise, T. A., Susman, E. S., Suva, L. J., Clines, G. A., Kominsky, S. L., Weber, K. L., Chirgwin, J. M., McCauley, L. K., Kozlow, W. (2006). Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA. IBMS BoneKEy 3: 15-42 [Full Text]  
• Chirgwin, J. M., Guise, T. A. (2006). Does Prostate-Specific Antigen Contribute to Bone Metastases?. Clin. Cancer Res. 12: 1395-1397 [Full Text]  
• Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., Meiller, T. (2006). Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. JCO 24: 945-952 [Abstract] [Full Text]  
• Schipani, E., Zallone, A., Strewler, G. J., Pike, J. W., Ferrari, S., Jiang, Y., Seeman, E. (2006). Meeting Report from the 27th Annual Meeting of the American Society for Bone and Mineral Research: September 23-27, 2005 in Nashville, Tennessee, USA. IBMS BoneKEy 3: 29-62 [Full Text]  
• Dai, Y., Yang, Y., MacLeod, V., Yue, X., Rapraeger, A. C., Shriver, Z., Venkataraman, G., Sasisekharan, R., Sanderson, R. D. (2005). HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo. J. Biol. Chem. 280: 40066-40073 [Abstract] [Full Text]  
• Ott, S. M. (2005). Editorial: Sclerostin and Wnt Signaling--The Pathway to Bone Strength. J. Clin. Endocrinol. Metab. 90: 6741-6743 [Full Text]  
• Bendre, M. S., Margulies, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., Swain, F., Ramani, V., Mohammad, K. S., Wessner, L. L., Martinez, A., Guise, T. A., Chirgwin, J. M., Gaddy, D., Suva, L. J. (2005). Tumor-Derived Interleukin-8 Stimulates Osteolysis Independent of the Receptor Activator of Nuclear Factor-{kappa}B Ligand Pathway. Cancer Res. 65: 11001-11009 [Abstract] [Full Text]  
• Clement-Lacroix, P., Ai, M., Morvan, F., Roman-Roman, S., Vayssiere, B., Belleville, C., Estrera, K., Warman, M. L., Baron, R., Rawadi, G. (2005). Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl. Acad. Sci. USA 102: 17406-17411 [Abstract] [Full Text]  
• Boissy, P., Andersen, T. L., Abdallah, B. M., Kassem, M., Plesner, T., Delaisse, J.-M. (2005). Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation. Cancer Res. 65: 9943-9952 [Abstract] [Full Text]  
• Moulopoulos, L. A., Gika, D., Anagnostopoulos, A., Delasalle, K., Weber, D., Alexanian, R., Dimopoulos, M. A. (2005). Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 16: 1824-1828 [Abstract] [Full Text]  
• Yaccoby, S. (2005). The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype. Clin. Cancer Res. 11: 7599-7606 [Abstract] [Full Text]  
• Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D., Matsumoto, T. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165 [Abstract] [Full Text]  
• Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., Chinnaiyan, A. M. (2005). Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 310: 644-648 [Abstract] [Full Text]  
• Agnelli, L., Bicciato, S., Mattioli, M., Fabris, S., Intini, D., Verdelli, D., Baldini, L., Morabito, F., Callea, V., Lombardi, L., Neri, A. (2005). Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations. JCO 23: 7296-7306 [Abstract] [Full Text]  
• Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M., Rizzoli, V. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106: 2472-2483 [Abstract] [Full Text]  
• Stewart, A. K., Fonseca, R. (2005). Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling. JCO 23: 6339-6344 [Abstract] [Full Text]  
• Hall, C. L., Bafico, A., Dai, J., Aaronson, S. A., Keller, E. T. (2005). Prostate Cancer Cells Promote Osteoblastic Bone Metastases through Wnts. Cancer Res. 65: 7554-7560 [Abstract] [Full Text]  
• Ehrlich, L. A., Chung, H. Y., Ghobrial, I., Choi, S. J., Morandi, F., Colla, S., Rizzoli, V., Roodman, G. D., Giuliani, N. (2005). IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106: 1407-1414 [Abstract] [Full Text]  
• Terpos, E., Dimopoulos, M.-A. (2005). Myeloma bone disease: pathophysiology and management. Ann Oncol 16: 1223-1231 [Abstract] [Full Text]  
• Moreaux, J., Cremer, F. W., Reme, T., Raab, M., Mahtouk, K., Kaukel, P., Pantesco, V., De Vos, J., Jourdan, E., Jauch, A., Legouffe, E., Moos, M., Fiol, G., Goldschmidt, H., Rossi, J. F., Hose, D., Klein, B. (2005). The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106: 1021-1030 [Abstract] [Full Text]  
• Ebeling, P. R. (2005). Defective Osteoblast Function May Be Responsible for Bone Loss from the Proximal Femur Despite Pamidronate Therapy. J. Clin. Endocrinol. Metab. 90: 4414-4416 [Full Text]  
• Morgan, T., Atkins, G. J., Trivett, M. K., Johnson, S. A., Kansara, M., Schlicht, S. L., Slavin, J. L., Simmons, P., Dickinson, I., Powell, G., Choong, P. F.M., Holloway, A. J., Thomas, D. M. (2005). Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor {kappa}B. Am. J. Pathol. 167: 117-128 [Abstract] [Full Text]  
• Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., Shaughnessy, J. Jr (2005). Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106: 296-303 [Abstract] [Full Text]  
• Ai, M., Holmen, S. L., Van Hul, W., Williams, B. O., Warman, M. L. (2005). Reduced Affinity to and Inhibition by DKK1 Form a Common Mechanism by Which High Bone Mass-Associated Missense Mutations in LRP5 Affect Canonical Wnt Signaling. Mol. Cell. Biol. 25: 4946-4955 [Abstract] [Full Text]  
• Oyajobi, B. O., Shipman, C. M., Mundy, G. R. (2005). Recent Insights into Myeloma Bone Disease. IBMS BoneKEy 2: 17-25 [Full Text]  
• Wang, F.-S., Lin, C.-L., Chen, Y.-J., Wang, C.-J., Yang, K. D., Huang, Y.-T., Sun, Y.-C., Huang, H.-C. (2005). Secreted Frizzled-Related Protein 1 Modulates Glucocorticoid Attenuation of Osteogenic Activities and Bone Mass. Endocrinology 146: 2415-2423 [Abstract] [Full Text]  
• Tickenbrock, L., Schwable, J., Wiedehage, M., Steffen, B., Sargin, B., Choudhary, C., Brandts, C., Berdel, W. E., Muller-Tidow, C., Serve, H. (2005). Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 105: 3699-3706 [Abstract] [Full Text]  
• Bredella, M. A., Steinbach, L., Caputo, G., Segall, G., Hawkins, R. (2005). Value of FDG PET in the Assessment of Patients with Multiple Myeloma. Am. J. Roentgenol. 184: 1199-1204 [Abstract] [Full Text]  
• Ranheim, E. A., Kwan, H. C. K., Reya, T., Wang, Y.-K., Weissman, I. L., Francke, U. (2005). Frizzled 9 knock-out mice have abnormal B-cell development. Blood 105: 2487-2494 [Abstract] [Full Text]  
• He, B., Lee, A. Y., Dadfarmay, S., You, L., Xu, Z., Reguart, N., Mazieres, J., Mikami, I., McCormick, F., Jablons, D. M. (2005). Secreted Frizzled-Related Protein 4 Is Silenced by Hypermethylation and Induces Apoptosis in {beta}-Catenin-Deficient Human Mesothelioma Cells. Cancer Res. 65: 743-748 [Abstract] [Full Text]  
• Gregory, C. A., Perry, A. S., Reyes, E., Conley, A., Gunn, W. G., Prockop, D. J. (2005). Dkk-1-derived Synthetic Peptides and Lithium Chloride for the Control and Recovery of Adult Stem Cells from Bone Marrow. J. Biol. Chem. 280: 2309-2323 [Abstract] [Full Text]  
• Abraham, R. S., Ballman, K. V., Dispenzieri, A., Grill, D. E., Manske, M. K., Price-Troska, T. L., Paz, N. G., Gertz, M. A., Fonseca, R. (2005). Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 105: 794-803 [Abstract] [Full Text]  
• Luo, Q., Kang, Q., Si, W., Jiang, W., Park, J. K., Peng, Y., Li, X., Luu, H. H., Luo, J., Montag, A. G., Haydon, R. C., He, T.-C. (2004). Connective Tissue Growth Factor (CTGF) Is Regulated by Wnt and Bone Morphogenetic Proteins Signaling in Osteoblast Differentiation of Mesenchymal Stem Cells. J. Biol. Chem. 279: 55958-55968 [Abstract] [Full Text]  
• Colucci, S., Brunetti, G., Rizzi, R., Zonno, A., Mori, G., Colaianni, G., Del Prete, D., Faccio, R., Liso, A., Capalbo, S., Liso, V., Zallone, A., Grano, M. (2004). T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730 [Abstract] [Full Text]